Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2022 Filed Feb 3, 2022 22:20 UTC |
Geist WilliamPresident, Protein Sciences
|
GrantCommon Stock | 2,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-002402 · rdgdoc.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 F1 · balance_after: Represents 2,490 shares of restricted stock for which the risk of forfeiture will lapse as to 830 shares on each of February 1, 2023, February 1, 2024 and February 1, 2025. Read SEC document |
| February 01, 2022 Filed Sep 29, 2022 20:10 UTC Amendment |
Geist WilliamPresident, Protein Sciences
|
GrantRestricted Stock Units · Derivative | 2,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-023243 · rdgdoc.xml · derivative · entry 1 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 Underlying: Common Stock · 2,490 shares Expires not disclosed F1 · security: This amendment is being filed solely to move this grant of restricted stock units from Table I (where it was originally reported) to Table II. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Represents 2,490 shares of restricted stock for which the risk of forfeiture will lapse as to 830 shares on each of February 1, 2023, February 1, 2024 and February 1, 2025. F3 · derivative.expiration_date: Represents 2,490 shares of restricted stock for which the risk of forfeiture will lapse as to 830 shares on each of February 1, 2023, February 1, 2024 and February 1, 2025. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:35 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 799 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001437749-22-002103 · rdgdoc.xml · derivative · entry 7 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,771 Underlying: Common Stock · 799 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:35 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 938 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0001437749-22-002103 · rdgdoc.xml · derivative · entry 6 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,010 Underlying: Common Stock · 938 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:35 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 799 | $125.05 | $99,914.95 |
DisclosureSEC source: 0001437749-22-002103 · rdgdoc.xml · nonDerivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 21:35 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 938 | $106.59 | $99,981.42 |
DisclosureSEC source: 0001437749-22-002103 · rdgdoc.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:02 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $150.78 | $0.00 |
DisclosureSEC source: 0001437749-21-027339 · rdgdoc.xml · derivative · entry 4 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,152 Underlying: Common Stock · 500 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options to purchase 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:02 UTC |
Kelderman KimPres. Diagnostics & Genom
|
SaleCommon Stock | 400 | $505.78 | $202,313.00 |
DisclosureSEC source: 0001437749-21-027339 · rdgdoc.xml · nonDerivative · entry 3 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.62 to $506.17, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:02 UTC |
Kelderman KimPres. Diagnostics & Genom
|
SaleCommon Stock | 100 | $503.76 | $50,376.00 |
DisclosureSEC source: 0001437749-21-027339 · rdgdoc.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:02 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionCommon Stock | 500 | $150.78 | $75,390.00 |
DisclosureSEC source: 0001437749-21-027339 · rdgdoc.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 799 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · derivative · entry 14 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 799 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 799 | $125.05 | $99,914.95 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 12 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 27,159 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · derivative · entry 13 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799 Underlying: Common Stock · 27,159 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 401 | $506.24 | $203,002.20 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 11 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 2,535 | $505.49 | $1,281,407.26 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 10 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,719 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 8,989 | $504.39 | $4,533,985.08 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 9 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,254 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 9,043 | $503.61 | $4,554,137.09 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 8 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,243 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 4,054 | $502.77 | $2,038,220.66 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 7 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,286 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 400 | $505.01 | $202,002.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 6 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,340 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 537 | $504.14 | $270,725.17 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,740 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 300 | $502.99 | $150,897.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 4 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,277 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 200 | $504.78 | $100,956.00 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,577 Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
SaleCommon Stock | 700 | $504.09 | $352,860.48 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,777 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:51 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 27,159 | $125.05 | $3,396,232.95 |
DisclosureSEC source: 0000914190-21-000405 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 21:29 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 200 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · derivative · entry 9 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,389 Underlying: Common Stock · 200 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 21:29 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 200 | $525.10 | $105,020.00 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 21:29 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 200 | $125.05 | $25,010.00 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 8,822 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · derivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,589 Underlying: Common Stock · 8,822 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 943 | $528.55 | $498,426.80 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.16 to $528.995, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,433 | $527.50 | $755,903.06 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,698 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.14 to $528.00, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 2,880 | $526.50 | $1,516,321.44 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,131 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.105 to $527.08, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 3,566 | $525.61 | $1,874,318.48 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,011 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.10 to $526.09, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 8,822 | $125.05 | $1,103,191.10 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 20:36 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 662 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000394 · edgar.xml · derivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,411 Underlying: Common Stock · 662 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 20:36 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 662 | $525.23 | $347,704.05 |
DisclosureSEC source: 0000914190-21-000394 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.10 to $525.59, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 20:36 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 662 | $125.05 | $82,783.10 |
DisclosureSEC source: 0000914190-21-000394 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:42 UTC |
STEER RANDOLPH CDirector
|
GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000400 · edgar.xml · derivative · entry 8 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:42 UTC |
STEER RANDOLPH CDirector
|
GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000400 · edgar.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,306 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:43 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Options (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000401 · edgar.xml · derivative · entry 9 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:43 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000401 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,806 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:39 UTC |
Nusse RoelandDirector
|
GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000398 · edgar.xml · derivative · entry 10 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/2021) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:39 UTC |
Nusse RoelandDirector
|
GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000398 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,959 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:41 UTC |
HIGGINS JOHN LDirector
|
GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000399 · edgar.xml · derivative · entry 11 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:41 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000399 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,606 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:37 UTC |
KEEGAN JOSEPH DDirector
|
GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000397 · edgar.xml · derivative · entry 6 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:37 UTC |
KEEGAN JOSEPH DDirector
|
GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000397 · edgar.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,333 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:37 UTC |
Bushman Julie LDirector
|
GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000393 · edgar.xml · derivative · entry 4 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/2021) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:37 UTC |
Bushman Julie LDirector
|
GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000393 · edgar.xml · nonDerivative · entry 1 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 674 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:37 UTC |
Vessey RupertDirector
|
GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000396 · edgar.xml · derivative · entry 5 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/20/21) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:37 UTC |
Vessey RupertDirector
|
GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000396 · edgar.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.